Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Kahn Swick & Foti, LLCCelsius Holdings, Inc. Securities Fraud Class Action Result of Health and Marketing Misrepresentations and Over 7% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLCKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 3, 2026 to file lead plaintiff applications in a...
- Kahn Swick & Foti, LLCHims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLCKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a...
- BetterLife Pharma Inc.BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded WarrantsFINAL PROSPECTUS ACCESSIBLE ON SEDAR+Vancouver, British Columbia--(September 11, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has filed a final short form prospectus (the "Final Prospectus") with the securities regulatory authorities in the provinces of British Columbia, Ontario and Alberta, in connection with the previously announced...
- FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA TreatmentThe Muscular Dystrophy Association (MDA) marks another milestone for the neuromuscular community with the U.S. Food and Drug Administration (FDA) approval of Isembyld (apitegromab-mstn), a monthly infusion treatment for people living with spinal muscular atrophy (SMA) who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. Isembyld (apitegromab-mstn) is the first and only muscle-targeted therapy for SMA, offering new hope for children and adults living with this neuromuscular disease. SMA is a leading genetic cause of death in infants and often requires lifelong support to maintain mobility, breathing, and independence. Today, with more treatments available, people are living longer, more independent lives. Read Scholar Rock’s announcement here.
- SueWallSt.comBiohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials — Biohaven Ltd (NYSE: BHVN) dropped $2.21, or about 14.73%, on...
- Robbins LLP Reminds Capricor Therapeutics, Inc. Stockholders of the Securities Fraud Class Action After the Company's Stock Fell 64%Robbins LLP is Investigating Allegations That Capricor Therapeutics, Inc. Misled Investors Regarding the Facts About the Path to FDA Approval for Deramioce
- Ynvisible Interactive Inc.Ynvisible Advances Commercial Program with Sapphiros, Announces CFO Appointment and Adoption of Semi-Annual Financial ReportingYnvisible Interactive Inc. (TSXV: YNV) (FSE: 1XNA) (OTCQB: YNVYF) (the "Company" or "Ynvisible") is pleased to provide an update on its strategic collaboration with Sapphiros, a consumer diagnostics company developing next-generation digital diagnostic tests for global markets.Sapphiros is progressing through clinical trials, with completion expected in the fourth quarter of 2026, while advancing regulatory, product...
- Adventist Health White Memorial HospitalNEW STUDY: WHITE MEMORIAL HOSPITALS GENERATE $1.2 BILLION IN ECONOMIC ACTIVITY AS L.A. HEALTHCARE SAFETY NET FACES GROWING PRESSURESHospitals support 5,500 jobs while serving communities facing significant health, economic and environmental disparities. — As hospitals serving high-need communities face growing financial pressures, a new study finds Adventist Health White...
- Hagens Berman Sobol Shapiro LLPBeta Bionics (BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSSBeta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026.The lawsuit follows a series of surprise revelations about the FDA's concerns over company's automated insulin delivery system ("iLet"), each of which sent the price of Beta Bionics shares sharply lower. National...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors to Contact the Firm Before the Deadline on November 2, 2026 for a Leadership RoleKaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may...
- Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business UpdateCellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.
- Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360ATLANTA, September 11, 2026--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360, Compass’ investigational psilocybin treatment, if approved.